查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1476379

到 2030 年糖尿病神經病變治療市場預測：按類型、治療、藥物類別、分銷管道、最終用戶和地區進行的全球分析

Diabetic Neuropathy Treatment Market Forecasts to 2030 - Global Analysis By Type (Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy, Peripheral Neuropathy and Other Types), Treatment, Drug Class, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球糖尿病神經病變治療市場規模為 46 億美元，預計預測期內複合年成長率為 7.5%，到 2030 年將達到 76 億美元。

糖尿病神經病變治療是一系列醫療干預措施和生活方式改變，旨在控制糖尿病引起的神經病變病變的症狀和併發症。糖尿病神經病變是一種由於與糖尿病相關的長期高血糖狀況神經病變。治療方法通常包括藥物、生活方式改變以及有時替代療法的組合，以緩解疼痛、改善神經功能並防止進一步的神經損傷。

根據美國疾病管制與預防中心 (CDC) 的美國糖尿病統計報告，2018 年有 3,420 萬美國（占美國人口的 10.5%）被臨床診斷患有糖尿病。

糖尿病盛行率上升

隨著被診斷為糖尿病的人數不斷增加，對有效神經病變治療的需求也顯著增加。這一趨勢是由生活方式的改變、人口老化以及早期診斷意識的提高等因素所推動的。因此，製藥公司和醫療保健提供者正在集中更多資源來開發和提供創新解決方案來解決糖尿病神經病變。因此，由於糖尿病盛行率的上升，市場正在經歷顯著的快速成長。

治療效果有限

儘管治療方法取得了進展，糖尿病神經病變的治療方法仍面臨挑戰，有限的療效仍然是一個重大問題。目前的治療方法通常著重於控制症狀，而不是解決根本原因。這項限制凸顯了市場需要持續研究和創新，以針對糖尿病患者神經病變的潛在機制制定更有效的策略。

治療進展

神經減壓手術、利用幹細胞的再生醫學和標靶藥物傳輸系統等創新治療方法正不斷出現。此外，神經刺激和透過穿戴式技術進行連續監測等非侵入性技術也顯示出前景。根據個別基因特徵客製化治療方案的精準醫學也是一個新領域。這些進展代表了糖尿病神經病變管理方法轉向更有效、個人化和整體性方法的轉變。

昂貴的治療費用

治療費用往往難以承擔，限制了獲得基本治療方法的機會，並加劇了已經在應對糖尿病相關神經病變挑戰的個人的負擔。這種經濟負擔旨在使這些治療方法更容易獲得和負擔得起，以確保糖尿病神經病變患者得到全面護理，這凸顯了干涉措施的迫切需求。結果，市場受到高昂費用的困擾，為尋求治療的患者造成了障礙。

COVID-19 的影響：

COVID-19 的爆發對糖尿病神經病變治療市場產生了重大影響。由於醫療資源的重新分配而導致診斷和治療的延誤，導致患者病情惡化。雖然遠端醫療在諮詢方面受到重視，但藥品供應鏈的中斷影響了藥品的取得。臨床試驗和研究也面臨挫折，減緩了新治療方法的發展。

局部神經病變預計將成為預測期內最大的部分

局部神經病變部分預計將成為預測期內最大的部分。目前的治療方法包括止痛藥物、物理治療和改變生活方式以控制血糖值。神經刺激技術和再生醫學等新治療方法有望解決潛在的神經損傷。然而，針對每位患者的需求量身定做的個人化方法仍然是最佳化糖尿病神經病變管理挑戰結果的重要研究領域。

預計診所業在預測期內的複合年成長率最高。

預計診所在預測期內將經歷最高的複合年成長率。這些診所提供各種服務，包括診斷測試、藥物管理、物理治療和生活方式諮詢。這些診所聘用熟練的醫療保健專業人員，例如神經科、內分泌科醫生和物理治療師，他們共同製定個人化的治療計劃。這些診所旨在透過管理症狀、預防併發症和促進整體健康來改善患者的生活品質。

比最大的地區

預計北美在預測期內將佔據最大的市場佔有率。主要參與者專注於開發創新治療方法滿足未滿足的患者需求。此外，有利的報銷政策和醫療基礎設施也有助於市場擴張。由於持續的研發活動，市場預計將持續成長，並有望為相關人員提供利潤豐厚的機會。

複合年成長率最高的地區：

由於糖尿病盛行率上升等多種因素，預計亞太地區在預測期內將維持最高的複合年成長率。市場提供了多種糖尿病神經病變的治療選擇，包括藥物、物理治療、神經刺激技術和生活方式改變。製藥公司正在積極開發新藥和治療方法來解決這個問題。醫療設備和診斷技術的進步也促進了市場的成長。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球糖尿病神經病變治療市場：依類型

  • 自主神經病變
  • 近端神經病變
  • 局部神經病變
  • 週邊神經病變
  • 其他類型

第6章全球糖尿病神經病變治療市場：依治療分類

  • 減緩疾病的進展
  • 緩解疼痛
  • 併發症的處理
  • 物理治療
  • 藥品
  • 其他治療

第7章全球糖尿病神經病變治療市場：依藥物類別

  • 非類固醇消炎劑
  • 鴉片類藥物
  • 抗憂鬱症
  • 抗癲癇藥
  • 其他藥物類別

第8章全球糖尿病神經病變治療市場：依通路

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 專科診所

第9章全球糖尿病神經病變治療市場：依最終用戶分類

  • 醫院
  • 診所
  • 門診手術中心
  • 居家照護環境
  • 其他最終用戶

第10章全球糖尿病神經病變治療市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • GlaxoSmithKline Plc
  • Lupin Ltd
  • Depomed, Inc
  • Astellas Pharma Inc
  • Meda Pharma GmBH & Co. KG
  • Glenmark Pharmaceuticals Ltd.
  • Eli Lilly and Company
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Johnson & Johnson
  • Pfizer Inc.
  • Novo Nordisk A/S
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Novartis AG
  • Asprius Lifesciences
  • Vertex Pharmaceuticals
Product Code: SMRC25925

According to Stratistics MRC, the Global Diabetic Neuropathy Treatment Market is accounted for $4.6 billion in 2023 and is expected to reach $7.6 billion by 2030 growing at a CAGR of 7.5% during the forecast period. Diabetic neuropathy treatment is the various medical interventions and lifestyle modifications aimed at managing the symptoms and complications of neuropathy caused by diabetes. It is a type of nerve damage that can result from prolonged high blood sugar levels associated with diabetes. The treatment approach typically involves a combination of medications, lifestyle changes, and sometimes alternative therapies to alleviate pain, improve nerve function, and prevent further nerve damage.

According to National Diabetes Statistics Report by the Centers for Disease Control and Prevention (CDC), it was found that 34.2 million U.S. individuals (10.5% of the U.S. population) were clinically diagnosed with diabetes in 2018.

Market Dynamics:

Driver:

Rising prevalence of diabetes

With more individuals being diagnosed with diabetes, the demand for effective neuropathy treatments has increased significantly. This trend is driven by factors such as lifestyle changes, aging populations, and heightened awareness leading to early diagnosis. As a result, pharmaceutical companies and healthcare providers are focusing more resources on developing and providing innovative solutions to address diabetic neuropathy. Thus, the market is experiencing a notable surge due to the rising prevalence of diabetes.

Restraint:

Limited efficacy of treatments

Despite advancements, treatments for diabetic neuropathy face challenges, with limited efficacy remaining a significant concern. Current therapies often focus on symptom management rather than addressing the underlying causes. This limitation underscores the need for continued research and innovation in the market to develop more effective strategies that target the root mechanisms of neuropathy in diabetic patients.

Opportunity:

Advancements in treatment

Innovative therapies like nerve decompression surgery, regenerative medicine using stem cells, and targeted drug delivery systems are emerging. Moreover, non-invasive techniques like neurostimulation and wearable tech for continuous monitoring show promise. Precision medicine tailoring treatments to individual genetic profiles is another frontier. These developments signify a shift towards more effective, personalized, and holistic approaches in managing diabetic neuropathy.

Threat:

High cost of treatments

With treatments often priced beyond affordability, access to essential therapies becomes restricted, exacerbating the burden on individuals already grappling with the challenges of managing diabetes-related neuropathy. This financial strain underscores the pressing need for interventions aimed at making these treatments more accessible and affordable to ensure comprehensive care for those affected by diabetic neuropathy. Therefore, the market is plagued by exorbitant costs, creating barriers for patients seeking care.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Diabetic Neuropathy Treatment market. Delays in diagnosis and treatment due to healthcare resource reallocation led to worsening patient conditions. Telemedicine gained prominence for consultations, while disruptions in the pharmaceutical supply chain affected medication availability. Clinical trials and research also faced setbacks, slowing down the development of new treatment options.

The focal neuropathy segment is expected to be the largest during the forecast period

The focal neuropathy segment is expected to be the largest during the forecast period. Current therapies include pain management medications, physical therapy, and lifestyle modifications to control blood sugar levels. Emerging treatments such as nerve stimulation techniques and regenerative medicine show promise in addressing underlying nerve damage. However, personalized approaches tailored to individual patient needs remain a key area of research to optimize outcomes in this challenging aspect of diabetic neuropathy management.

The clinics segment is expected to have the highest CAGR during the forecast period

The clinics segment is expected to have the highest CAGR during the forecast period. These clinics provide a range of services, including diagnostic testing, medication management, physical therapy, and lifestyle counseling. They employ skilled healthcare professionals such as neurologists, endocrinologists, and physical therapists who work collaboratively to develop personalized treatment plans. These clinics aim to improve patients' quality of life by managing symptoms, preventing complications, and promoting overall well-being.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Key players are focusing on developing innovative therapies to address the unmet needs of patients. Additionally, favorable reimbursement policies and healthcare infrastructure are contributing to market expansion. With ongoing research and development activities, the market is poised for continued growth and is expected to offer lucrative opportunities for stakeholders.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to various factors such as the increasing prevalence of diabetes. The market offers a range of treatment options for diabetic neuropathy, including medications, physical therapy, nerve stimulation techniques, and lifestyle modifications. Pharmaceutical companies are actively developing new drugs and therapies to address this condition. Technological advancements in medical devices and diagnostics have also contributed to the growth of the market.

Key players in the market

Some of the key players in Diabetic Neuropathy Treatment market include GlaxoSmithKline Plc, Lupin Ltd, Depomed, Inc, Astellas Pharma Inc, Meda Pharma GmBH & Co. KG, Glenmark Pharmaceuticals Ltd., Eli Lilly and Company, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Pfizer Inc., Novo Nordisk A/S, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., AbbVie Inc., Novartis AG, Asprius Lifesciences, and Vertex Pharmaceuticals.

Key Developments:

In December 2023, Vertex Pharmaceuticals received FDA approval for CRISPR-based gene editing therapy, a strategy focused on developing and promoting non-opioid pain relievers Based on Vertex's Phase 2 clinical trial results for VX-548, highlighting alternative pain management strategies in diabetic peripheral neuropathy Thiah of the safe and consistent with the search for more effective treatments.

In July 2023, Asprius Lifesciences recently started treating diabetic neuropathy, a disease that causes nerve damage in different parts of the body the company has filed patents for a patented drug combination (FDC), indicating potential for peripheral nerve block.

Types Covered:

  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy
  • Peripheral Neuropathy
  • Other Types

Treatments Covered:

  • Slow Progression of Diseases
  • Pain Relieving
  • Managing Complications
  • Physiotherapy
  • Drugs
  • Other Treatments

Drug Classes Covered:

  • Non-Steroidal Anti-Inflammatory Drugs
  • Opioid
  • Anti-Depressants
  • Anti-Seizure
  • Other Drug Classes

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics

End Users Covered:

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Diabetic Neuropathy Treatment Market, By Type

  • 5.1 Introduction
  • 5.2 Autonomic Neuropathy
  • 5.3 Proximal Neuropathy
  • 5.4 Focal Neuropathy
  • 5.5 Peripheral Neuropathy
  • 5.6 Other Types

6 Global Diabetic Neuropathy Treatment Market, By Treatment

  • 6.1 Introduction
  • 6.2 Slow Progression of Diseases
  • 6.3 Pain Relieving
  • 6.4 Managing Complications
  • 6.5 Physiotherapy
  • 6.6 Drugs
  • 6.7 Other Treatments

7 Global Diabetic Neuropathy Treatment Market, By Drug Class

  • 7.1 Introduction
  • 7.2 Non-Steroidal Anti-Inflammatory Drugs
  • 7.3 Opioid
  • 7.4 Anti-Depressants
  • 7.5 Anti-Seizure
  • 7.6 Other Drug Classes

8 Global Diabetic Neuropathy Treatment Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies
  • 8.5 Specialty Clinics

9 Global Diabetic Neuropathy Treatment Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Clinics
  • 9.4 Ambulatory Surgical Centers
  • 9.5 Homecare Settings
  • 9.6 Other End Users

10 Global Diabetic Neuropathy Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 GlaxoSmithKline Plc
  • 12.2 Lupin Ltd
  • 12.3 Depomed, Inc
  • 12.4 Astellas Pharma Inc
  • 12.5 Meda Pharma GmBH & Co. KG
  • 12.6 Glenmark Pharmaceuticals Ltd.
  • 12.7 Eli Lilly and Company
  • 12.8 Abbott Laboratories
  • 12.9 F. Hoffmann-La Roche Ltd
  • 12.10 Johnson & Johnson
  • 12.11 Pfizer Inc.
  • 12.12 Novo Nordisk A/S
  • 12.13 Merck & Co., Inc.
  • 12.14 Teva Pharmaceutical Industries Ltd.
  • 12.15 AbbVie Inc.
  • 12.16 Novartis AG
  • 12.17 Asprius Lifesciences
  • 12.18 Vertex Pharmaceuticals

List of Tables

  • Table 1 Global Diabetic Neuropathy Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Diabetic Neuropathy Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Diabetic Neuropathy Treatment Market Outlook, By Autonomic Neuropathy (2021-2030) ($MN)
  • Table 4 Global Diabetic Neuropathy Treatment Market Outlook, By Proximal Neuropathy (2021-2030) ($MN)
  • Table 5 Global Diabetic Neuropathy Treatment Market Outlook, By Focal Neuropathy (2021-2030) ($MN)
  • Table 6 Global Diabetic Neuropathy Treatment Market Outlook, By Peripheral Neuropathy (2021-2030) ($MN)
  • Table 7 Global Diabetic Neuropathy Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 8 Global Diabetic Neuropathy Treatment Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 9 Global Diabetic Neuropathy Treatment Market Outlook, By Slow Progression of Diseases (2021-2030) ($MN)
  • Table 10 Global Diabetic Neuropathy Treatment Market Outlook, By Pain Relieving (2021-2030) ($MN)
  • Table 11 Global Diabetic Neuropathy Treatment Market Outlook, By Managing Complications (2021-2030) ($MN)
  • Table 12 Global Diabetic Neuropathy Treatment Market Outlook, By Physiotherapy (2021-2030) ($MN)
  • Table 13 Global Diabetic Neuropathy Treatment Market Outlook, By Drugs (2021-2030) ($MN)
  • Table 14 Global Diabetic Neuropathy Treatment Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 15 Global Diabetic Neuropathy Treatment Market Outlook, By Drug Class (2021-2030) ($MN)
  • Table 16 Global Diabetic Neuropathy Treatment Market Outlook, By Non-Steroidal Anti-Inflammatory Drugs (2021-2030) ($MN)
  • Table 17 Global Diabetic Neuropathy Treatment Market Outlook, By Opioid (2021-2030) ($MN)
  • Table 18 Global Diabetic Neuropathy Treatment Market Outlook, By Anti-Depressants (2021-2030) ($MN)
  • Table 19 Global Diabetic Neuropathy Treatment Market Outlook, By Anti-Seizure (2021-2030) ($MN)
  • Table 20 Global Diabetic Neuropathy Treatment Market Outlook, By Other Drug Classes (2021-2030) ($MN)
  • Table 21 Global Diabetic Neuropathy Treatment Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 22 Global Diabetic Neuropathy Treatment Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 23 Global Diabetic Neuropathy Treatment Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 24 Global Diabetic Neuropathy Treatment Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 25 Global Diabetic Neuropathy Treatment Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 26 Global Diabetic Neuropathy Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 27 Global Diabetic Neuropathy Treatment Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 28 Global Diabetic Neuropathy Treatment Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 29 Global Diabetic Neuropathy Treatment Market Outlook, By Ambulatory Surgical Centers (2021-2030) ($MN)
  • Table 30 Global Diabetic Neuropathy Treatment Market Outlook, By Homecare Settings (2021-2030) ($MN)
  • Table 31 Global Diabetic Neuropathy Treatment Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.